Metabolic Syndrome Is a Strong Risk Factor for Minor Ischemic Stroke and Subsequent Vascular Events

Guang-Sheng Wang1, Dao-Ming Tong1, Xiao-Dong Chen1

  • 1Department of Neurology, Affiliated Shu Yang People's Hospital, XuZhou Medical University, XuZhou, China.

Plos One
|August 19, 2016
PubMed
Abstract

Insights

Metabolic syndrome (MetS) significantly increases the risk of minor ischemic stroke (MIS) and subsequent vascular events (SVE). Patients with MIS and MetS face a higher risk of SVE, highlighting the importance of MetS prevention.

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Metabolic Disorders

Background:

  • Minor ischemic stroke (MIS) is a significant global health concern due to its high incidence.
  • Investigating risk factors for MIS and subsequent vascular events (SVE) is crucial for public health.

Purpose of the Study:

  • To determine if metabolic syndrome (MetS) is a strong risk factor for minor ischemic stroke (MIS).
  • To assess the association between MetS and the risk of subsequent vascular events (SVE) in patients with MIS.

Main Methods:

  • A retrospective cohort study involving 1361 Chinese neurologic outpatients over 25 years old without prior stroke history.
  • Metabolic syndrome (MetS) was diagnosed using the International Diabetes Federation criteria.
  • Minor ischemic stroke (MIS) diagnosis was confirmed via magnetic resonance imaging (MRI) using diffusion-weighted images or fluid-attenuated inversion recovery.

Main Results:

  • Out of 1361 patients, 753 (55.3%) were diagnosed with MIS; 303 (40.2%) of these also had MetS.
  • MIS patients with MetS showed significant correlations with abdominal obesity, hypertension, elevated blood glucose, and dyslipidemia compared to controls.
  • MetS was significantly associated with an increased risk of SVE in patients with MIS (RR, 3.3; 95% CI, 1.799-6.210), along with older age and high blood glucose.

Conclusions:

  • Metabolic syndrome (MetS) is identified as a strong risk factor for minor ischemic stroke (MIS).
  • Patients with MIS and co-existing MetS are at a considerably higher risk for subsequent vascular events (SVE).
  • Further research is needed to explore MetS prevention strategies for reducing MIS and SVE incidence.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.5K
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
562
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
697
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.3K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
873